Pharmaceuticals
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial
SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label, Controlled, Mu...
2023-12-11 20:00
1751
HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors
WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to...
2023-12-11 20:00
2264
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results
- A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, MD, PhD, Academician of the Chinese Academy of Engineering - 70% of the patients enrolled in phase Ib study were previously treated with CDK4/6 inhibitors - Demonstrated a confirmed objecti...
2023-12-11 18:55
1912
Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib
SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study ...
2023-12-11 13:30
1825
Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%
SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest efficacy and safety...
2023-12-11 13:14
1826
Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery
CAMBRIDGE, Mass., Dec. 10, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and Evive Biotech, a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwid...
2023-12-11 09:00
1881
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published inThe Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting and Ex...
2023-12-10 18:00
2497
PharmaBlock Officially Joins United Nations Global Compact
NANJING, China, Dec. 8, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has officially joined the United Nations Global Compact (UNGC), which not only affi...
2023-12-08 12:37
2205
Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy
* RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study. * Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have progressed on CDK4/6 inhibitors (CDK4/6is) and ...
2023-12-08 07:39
2544
2023 SABCS - TransThera announces an oral presentation of tinengotinib clinical data in breast cancer
NANJING, China, Dec. 7, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announced that an oral presentation of tinengotinib clinical data in breast cancer was delivered at 202...
2023-12-07 21:00
1762
GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant
Starts undertaking quality evaluation and characterization of iPSCs in
accordance with ISO standards
PALO ALTO, Calif., Dec. 6, 2023 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://www.ipeace.com
2023-12-06 22:30
1911
WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader
SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced it has successfully passed an on-site GMP audit by a global vaccine leader at its first standalone CDMO site in Suzhou,China. The audit m...
2023-12-06 17:00
2078
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023
First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023 /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4...
2023-12-05 21:00
2235
J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023
SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that
early results of the Phase 1/2 study of its novel, orally administered 4th
generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference
held inSingapore from 1st to 3rd December 2023.
2023-12-05 15:16
1801
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investiga...
2023-12-04 21:50
2005
Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis
CHENGDU, China, Dec. 4, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD). This first cl...
2023-12-04 21:13
1653
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt,Germany. Under the terms of the agreement, Merck will be granted an exclusive licens...
2023-12-04 21:05
2022
Crystal Pharmatech's CDMO Business Unit successfully passed the dual certification of GMP and GDP conducted by SGS
SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Recently, Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services (CFS) successfully obtained dual certification in Good Manufacturing Practices (GMP)[1] and Good Distribution Practices (GDP)[2] from SGS, an internationally recognized thi...
2023-12-04 21:00
1538
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
CAMBRIDGE, Mass., Dec. 3, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced today it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation. Lycia...
2023-12-04 13:19
1573
Registrational Phase III CLARIFY trial in prostate cancer commences
SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its r...
2023-11-30 22:16
2099
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 312 media titles]
2026-02-03 11:00
Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 303 media titles]
2026-02-03 12:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 286 media titles]
2026-02-01 19:35